Table 1.

Key completed trials involving HSP90 inhibitors

Drug name	Trial information	Stratification	End point	ORR	Comments
Ganetespib	NCT01031225 n=99 Phase II	Cohort A: mutant RAS Cohort B: mutant EGFR Cohort C: wild type	PFS at 16 weeks Cohort A: 13.3% Cohort B: 5.9% Cohort C: 13.9%	4% (only seen in patients with ALK translocation)	Two deaths (one cardiac arrest and one renal failure)
	GALAXY-1 NCT01348126 n=255 Phase II Combination drug: docetaxel	LDH RAS mutation Time since advanced disease Performance status Smoking	OS: HR 0.69 PFS: HR 0.70	15% in the combination arm 11% in stand-alone arm	Best response achieved in patients with >6 months since advanced diagnosis (HR 0.41)
AUY922	NCT01922583 n=112 Phase II	EGFR-mutated KRAS-mutated ALK-rearranged Wild type	ORR and SD at 18 weeks Overall: 13%	EGFR: 18% KRAS: 0% ALK: 25% Wild type: 13%	SD achieved in some crizotinib-resistant patients
Retaspimycin (IPI-504)	NCT00431015 n=76 Phase II	EGFR wild-type EGFR-mutated	ORR of 7%	EGFR wild-type: 10% EGFR-mutated: 4%	Grade 3 liver dysfunction in 11% of patients

Abbreviations: ORR, overall response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; SD, stable disease; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; LDH, lactate dehydrogenase.